Naučne publikacije akademskog osoblja
Datum kreiranja: 23.01.2014.

Ivica Pejčić

Dodatne informacije

  • Lični podaci

  • Datum rođenja: 15.06.1957.
  • Mesto rođenja: Niš
  • Obrazovanje

  • Fakultet: Medicinski fakultet u Nišu
  • Odsek / Grupa / Smer: Medicina
  • Godina diplomiranja: 1982.
  • Spisak publikacija

  • Monografije i poglavlja u monografijama:

     


    Cvetanović Ana, Popović Lazar, Živković N, Matovina-Brko Gorana, Filipović Sladjana, Kostić Milos, Vrbić Svetislav, Pejčić Ivica. Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A New Key in the Hands of Oncologists. U: Horizons in Cancer Research.Volume 65: Watanabe (ed). Nova Science Publishers, Inc; New York 2017; 65-89.


    Монографија:  Ana Cvetanovic, Lazar Popovic, Nikola Zivkovic, Gorana Matovina-Brko, Sladjana Filipovic, Kostic Milos, Svetislav Vrbic, Ivica Pejcic Immune Checkpoint Inhibitors in Treatment of Solid Tumors: A New Key in Hands of Oncologists.U: Horizon in Cancer Research. Volume 65: Watanabe (ed), Nova Science Publishers, Inc; New York 2017; 65-89


    Практикум:  Ivan Petković, Ivica Pejčić. Preporuke za lečenje primarnog medijastinalnog B krupnoćelijskog limfoma (PMBCL). U: Vodič za dijagnostiku i lečenje zrelih B ćelijskih neoplazmi i Hočkinovog limfoma, Beograd oktobar 2017:17-18

  • Knjige i udžbenici:

    1. Radmila Veličković. Farmakoterapija. Medicinski fakultet Univerziteta u Nišu, Galaksija Niš, 2011


    2. Filipović Sladjana, Stanojević Zorica, Vrbić Svetislav, Pejčić Ivica. Osnovi kliničke onkologije. Medicinski fakultet Univerziteta u Nišu, Grafika Galeb Niš,2009.


    3.  Ana Cvetanovic, Sladjana Filipovic, Svetislav Vrbic, Ivica Pejcic, Lazar Popovic. Head and Neck Cancer: Epidemiology, Management and Treatment Outcomes. Side Effects of Cetuximab Rash. Medical Oncology Unit, University Clinic Nis, Serbia. Madison R.Hall 2015. ISBN: 978-1-63482-113-1 


     


     

  • Radovi u časopisima sa IMPACT faktorom:

    1. Ivan Petković, Slavica Stojnev, Aleksandar Popović, Miljan Krstić, Ivica Pejčić. Extranodal NK/T–cell lymphoma, nasal type overlapping aggressive NK–cell leukemia in course of progression. UHOD-Uluslar Hematol 2020; 30 (4): xx-xx.    doi:10.4999/UHOD    IF2019: 2.323       (M23)             5-IF 2019: 2.01


    2. Miljana Dzunic, Marija Andjelkovic-Apostolovic, Svetislav Vrbic, Ivica Pejcic, Ivan Petkovic, Ana Cvetanovic, Sasa Dinic. Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLFOX4. J BUON 2020; 25 (1): 212-9.  PMID: 32277634  IF (2019): 1.695 (M23)


    3. Miljana Dzunic, Ivan Petkovic, Ana Cvetanovic, Svetislav Vrbic, Ivica Pejcic. Current and future targets and therapies in metastatic colorectal cancer - Status Change. J BUON 2019; 24 (5): 1785-92. PMID: 31786838 IF (2019): 1.695 (M23)


    4.  Ana Cvetanovic, Ivica Pejcic, Nikola Zivkovic, Dane Krtinic, MIlos Kostic, Lazar Popovic. Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer? J BUON 2019; 24 (2): 516-21. PMID: 31127999 IF (2019): 1.695 (M23)


    5. Ivan Petković, Ivica Pejčić, Danica Tiodorović, Miljan Krstić, Slavica Stojnev, Svetislav Vrbić. Transformation of primary cutaneous follicle centre lymphoma into primary cutaneous diffuse large B-cell lymphoma of other type. Postepy Dermatol Alergol 2017; 34 (6):  625-8. doi:10.5114/pdia.2017.66625   PMID: 29422831  IF 2017: 1.471  (M23) 


    6. Ivan Petković, Slavica Stojnev, Miljan Krstić, Ivica Pejčić, Svetislav Vrbić. Sinchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence? Vojnosanit Pregl 2016; 73 (11): 1072-75.  doi:10.2298/VSP150425128P  PMID: 29341562  IF 2016: 0.367 (M23)


    7. Biljana Kocic, Sladjana Filipovic, Svetislav Vrbic, Ivica Pejcic, Natasa Rancic, Ana Cvetanovic, Dusan Milenkovic. Stressful life events and breast cancer risk: a hospital-based case-control study. J BUON 2015; 20 (2): 487-91. PMID:26011340  IF 2015: 0.880  (M23)  


    8. Lidija Kandolf-Sekulović, Nada Babović, Mirjana Balić, Borislava Nikolin, Dejan Nikolić, Zlata Janjić, Neven Jokić, Željko Mijušković, Milica Rajović, Marijan Novaković, Svetislav Vrbić, Ivica Pejčić, Predrag Kovačević, Dragan Mihajlović, Tatjana Roganović, Vicko Ferenc, Jelena Nikolić, Marijan Marinković, Zorana Bizetić. Clinicopathological characteristics, diagnosis and treatment of melanoma in Serbia-the Melanoma Focus Study. Vojnosanit Pregl 2015; 72 (4): 312-6.  doi: 10.2298/VSP 131014052K PMID: 26040176 IF 2015: 0.355 (M23)


    9. Ivan Petković, Ivica Pejčić, Svetislav Vrbić. Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma? Contemp Oncol (Pozn) 2014; 18 (6): 377-83.  doi:10.5114/wo.2014.45111  PMID: 25784834 IF 2013: 0.215 (M23)  


    10. Ivica Pejcic, Ivan Petkovic, Svetislav Vrbic, Sladjana Filipovic, Mirjana Balic, Ana Cvetanovic. Mantle cell lymphoma-current literature overview. J BUON 2014; 19 (2): 342-9.   PMID:24965390  IF 2014: 0.761  (M23)  


    11. Ivan Petković, Miljan Krstić, Ivica Pejcić, Svetislav Vrbić, Slavica Stojnev, Ana Cvetanović, Mirjana Balić, Mirjana Todorović. Renal infiltration of Follicular Lymphoma. Turk J Hematol 2014; 31 (3): 315-6.       doi: 10.4274/Tjh.2014.0013  PMID: 25330530  IF 2014: 0.360  (M23)


    12. Ana Cvetanovic, Svetislav Vrbic, Sladjana Filipovic, Ivica Pejcic, Dusan Milenkovic, Nikola Zivkovic, Milos Kostic, Ivan Petkovic. Clinical benefit of Cetuximab and prognostic values of Cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analasys. J BUON 2014; 19 (1): 83-90.    PMID: 24659647    IF 2014: 0.761 (M23)


    13. Ana Cvetanovic, Svetislav Vrbic, Sladjana Filipovic, Ivica Pejcic, Dusan Milenkovic, Nikola Zivkovic. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience. J BUON 2013; 18 (3): 641-6.    PMID: 24065477   IF 2013: 0.761  (M23)


    14. Svetislav Vrbic, Ivica Pejcic, Sladjana Filipovic, Biljana Kocic, Miodrag Vrbic. Current and future anti-HER2 therapy in breast cancer. J BUON 2013; 18 (1): 4-16.   PMID: 23613383  IF 2013: 0.761  (M23)


    15. Petric Aleksandra, Stojanov Dragan, Lilic Vekoslav, Filipovic Sladjana, Bosnjakovic Petar, Zivadinovic Radomir, Lilic Goran, Todorovska Ilinka, Vrbic Svetislav, Pejcic Ivica. The application of magnetic resonance imaging in preoperative evaluation of patients with endometrial carcinoma. J BUON 2011; 16 (3): 492-7.    PMID: 22006756  IF 2011: 0.607 (M23)


    16. Kocic Biljana, Filipovic Sladjana, Vrbic Svetislav, Pejcic Ivica. Breast cancer in women under 40 years of age. J BUON 2011; 16 (4): 635-9.  PMID: 22331714  IF 2011: 0.607 (M23)


    17. Ivica Pejčić, Svetislav Vrbić, Slađana Filipović, Mirjana Šćekić, Ivan Petković, Ljiljana Pejčić, Nebojša Đenić. Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site. Vojnosanit Pregl 2010; 67 (9): 723-31.  doi: 10.2298/VSP1009723P  PMID: 20954411         IF 2010: 0.199   (M23)


    18. Ivica Pejcic, Svetislav Vrbic, Sladjana Filipovic, Mirjana Scekic, Ivan Petković, Ljiljana Pejcic. Concurrent chemoimmunotherapy: is still the best option for patients with good performance status. J BUON 2010; 15 (3): 470-4.  PMID: 20954411   IF 2010: 0.482   (M23)


    19. Svetislav Vrbic, Ivica Pejcic, Miodrag Vrbić, Sladjana Filipovic. Therapy of stage IVB anaplastic thyroid carcinoma: single institution expirience. J BUON 2009; 14 (1): 41-4.   PMID: 19373945                       IF 2009: 0.600  (M23)


     


     


     


     



     

  • Radovi u ostalim časopisima:

    1. Ivan Petković, Aleksandar Popović, Miljana Džunić, Ivica Pejčić. Nodal and extranodal peripheral T/NK-cell neoplasms-current aspects. Acta Fac Med Naiss 2020; 37 (2): 99-120.  doi: 10.5937/afmnai37-24708   (M51)


    2. Miljana Džunić, Bojana Pejčić, Marija Anđelković-Apostolović, Svetislav Vrbić, Ivica Pejčić, Ivan Petković. Predictors of therapy response and early reccurence in patients with potentially resectabile colorectal liver metastases treated with bevacizumab and FOLFOX4 as a conversion therapy. Acta Medica Medianae 2019; 58 (3): 72-9.      doi: 10.5633/amm.2019.0310   (M51)


    3. Ivica Pejčić, Ivan Petković, Ana Cvetanović, Irena Conić. Single center experience study with Pembrolizumab in patients with BRAF mutant negative metastatic melanoma. Acta Fac Med Naiss 2018; 35 (4): 267-72. doi: 10.2478/afmnai-2018-0028 (M51)


    4. Ana Cvetanović, Slađana Filipović, Nikola Živković, Miloš Kostić, Svetislav Vrbić, Ivica Pejčić. Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer? Acta Fac Med Naiss 2016; 33 (4): 237-46.  doi: 10.1515/afmnai-2016-0026 (M51)


    5. Ivan Petković,  Ivica Pejčić, Svetislav Vrbić. Proteazomni inhibitori-racionala kliničke primene u tretmanu multiplog mijeloma. Racionalna Terapija 2016; 8 (2): 25-33.  doi: 10.5937/racter8-10447  (M52)


    6. Ivana Krstić, Marina Deljanin Ilić, Svetislav Vrbić, Ivica Pejčić. Significance of Echocardiography in the Assessment of Left Ventricular Function in Patients Receiving Combined Adjuvant Treatment with Anthracyclines and Trastuzumab. Acta Fac Med Naiss 2015; 32 (3): 181-7.  doi: 10.1515/afmnai-2015-0018 (M51)


    7. Ivan Petković, Miljan Krstić, Slavica Stojnev, Ivica Pejčić, Svetislav Vrbić. Extensive bone marrow involvement in Hodgkin lymphoma patient. Acta Fac Med Naiss 2014; 31 (4): 261-5.     doi: 10.2478/afmnai-2014-0032   (M52)    


    8. Ivica Pejčić, Svetislav Vrbić, Mirjana Todorović, Ivan Petković, Mirjana Balić, Ana Stanković. Cancer of unknown primary site syndrome-CUP syndrome-diagnostic and therapeutic dillemas. Acta Fac Med Naiss 2014; 31 (2): 87-94.   doi: 10.2478/afmnai-2014-0010  (M52)


    9. Ivan Petković, Ivica Pejčić, Svetislav Vrbić. New frontiers of target therapy in oncology: acute promyelocytic leukemia. Acta Fac Med Naiss 2014; 31 (1): 17-28.   doi:10.2478/afmnai-2014-0002  (M52)


    10. Ivan Petković,  Dragan Mihailović, Miljan Krstić,  Ivica Pejčić, Svetislav Vrbić, Mirjana Balić. Burkitt lymphoma in elderly patients - a case report. Acta Fac Med Naiss 2013; 30 (2): 103-9.   doi: 10.2478/v10283-012-0044-0  (M52) 


    11. Ivan Petković, Dragan Mihailović, Miljan Krstić,  Ivica Pejčić, Svetislav Vrbić, Mirjana Balić. Primary mantle cell lymphoma of gastrointestinal tract - a case report. Acta Medica Medianae 2012; 51 (3): 41-6.  doi: 10.5633/amm.2012.0307   (M52) 


    12. Pejčić Ivica, Vrbić Svetislav. Application of anti CD-20 monoclonal antibodies in the treatment of lymphoproliferative diseases. Arch Oncol 2009; 17 (3-4): 65-7.  doi: 10.2298/AOO0904065P (M52) 


    13. Antić Ana, Filipović Slađana, Pejčić Ivica, Vrbić SvetislavPrimena produkata od krvi kod onkoloških bolesnika lečenih radio i hemioterapijom. Acta Medica Medianae 2008; 47 (4): 13-8. 


    14. Filipović Slađana, Filipović Aleksandra, Pejčić Ivica, Vrbić Svetislav, Stanojević Zorica, Mišić Ivana. Biomarkers in breast cancer. Jugoslav Med Biohem 2006; 25: 355-61.


    15. Filipović Slađana, Filipović Aleksandra, Stojiljković V, Mišić Ivana, Vrbić Svetislav, Pejčić Ivica, Stanojević Zorica. Breast cancer – clinical implication. Jugoslav Med Biohem 2007; 26: 134-43.


    16. Svetislav Vrbic, Sladjana Filipovic, Pejcic Ivica. Adjuvant chemotherapy of premenopausal breast cancer patients under 35 years of age. J BUON 2003; 8: 101-4. PMID: 17472234


    17. Svetislav Vrbić, Sladjana Filipovic, Ivica Pejcic,Miodrag Vrbic, Aleksandra Filipovic. Sensitivity, specificity, positive and negative predictive value of serum S-100 beta protein in patients with malignant melanoma. J BUON 2003; 8: 139-41. PMID: 17472240


    18. Svetislav Vrbic, Sladjana Filipovic, Ivica Pejcic, Miodrag Vrbic. Simultaneous or sequential chemotherapy for locally advanced breast cancer. J BUON 2003; 8: 317-20. PMID: 17472271


    19. Ivica Pejcic, Svetislav Vrbic, Sladjana Filipovic, Stojan Radic, Ljiljana Pejcic. Chemotherapy in carcinomas of unknown primary site. J BUON 2004; 9: 27-31.  PMID: 17385824


    20. Pejčić Ljiljana, Bjelaković Bojko, Miljković B, Mileusnić R, Frujić G, Pejčić Ivica. Prirodna istorija-muskularnih septalnih-defekata. Acta Fac Med Naiss 2006; 23 (1): 25-9.


    21.  Vrbić Svetislav, Pejčić Ivica, Filipović Slađana, Radić Stojan. Sequential dose-dense single agent chemotherapy for locally advanced breast cancer. Arch Oncol 2003; 11 (3): 149.


    22 Pejčić Ivica, Vrbić Svetislav, Šćekić Mirjana. Combined chemotherapy and irradiation in anaplastic thyroid carcinoma. Arch Oncol 2003; 11 (3): 187.


    23. Pejčić Ivica, Vrbić Svetislav, Filipović Bratislav, Petrović M. Serum ferritin levels-a useful marker in Non-Hodgkin Lymphomas? Arch Oncol 1996; 4 (2): 83-5.


    24. Filipović S, Filipović B, Baltić V, Pejčić I, Vrbić S, Stojanović D, Kocić B, Ljubenković S. Tumour markers Ca 15-3, TPA, CEA as predictive factors in breast cancer patients. Arch  Oncol 1996; 4 (3): 151-4.


    25. Filipović Slađana, Pejčić Ivica, Vrbić Svetislav, Jovanović B, Antović Jovan, Bakić Milorad. Blood coagulation and fibrinolysis parameters changes in patients with metastatic melanoma. Arch Oncol 1998; 6 (3): 93-4.


    26. Bašić Hakija, Nikolić D, Pejčić Ivica, Marković Milan, Paunković Ljiljana, Lazarević V. Immunoreactivity of HMB-45 antibody in pigmented skin tumors. Arch Oncol 1998; 2: 128. 


    27. Pejčić Ivica, Vrbić Svetislav, Šćekić Mirjana, Filipović Slađana, Pejčić Ljiljana, Filipović Aleksandra. The effect of combined chemotherapy with or without potentiation with interferon alpha or tamoxifen for melanoma. Arch Oncol 2004; 12 (1): 25-8.


    28. Veselinović Slavica, Filipović Slađana, Projević Miodrag, Stanojević D, Burić Milan, Filipović S, Pejčić Ivica, Vrbić Svetislav. The effects of tamoxifen on plasma lipid levels in postmenopausal breast cancer patients. Arch Oncol 1996; 4 (2): 59.


     

  • Radovi na naučnim skupovima međunarodnog značaja:

    1. Jelena Jelicic, Milena Todorovic, Bosko Andjelic, Darko Antic, Olivera Markovic,  Ivan Petkovic, Aleksandra Sretenovic, Jelena Bila, Vojin Vukovic, Vladislava Djurasinovic, Mihailo Smiljanic, Ivica Pejicic, Biljana Mihaljevic. The absolute lymphocyte count as independent pararmeter may predict prognosis of follicular lymphoma patients [Meeting Abstract]. Haematologica 2016; 101 (Suppl 1): 753.   (M34) 


    2. Jelena Jelicic, Milena Todorovic Balint, Darko Antic, Bosko Andjelic, Olivera Markovic, Ivan Petkovic, Aleksandra Sretenovic, Jelena Bila, Vojin Vukovic, Vladislava Djurasinovic, Mihailo Smiljanic, Ivica Pejicic, Biljana Mihaljevic. Analysis of clinical parameters, absolute lymphocyte count in patients with diffuse large B cell lymphoma [Meeting Abstract]. Haematologica 2016; 101 (Suppl 1): 706. (M34) 


    3. Mihaljević B, Antić D, Anđelić B, Todorović M, Vukićević T, Nikolić V, Pejčić I, Petković I, Popović L, Anđelković N, Sretenović S, Smiljanić M, Marković O. Prognostic significance of the Ki-67 index in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP-experience of Serbian Lymphoma Study Group. Abstract Book, 16th Congress of the European Hematology Association, London-June 2011. Haematologica 2011; 96 (Suppl 2): 575-6.


    4. Mihaljevic Biljana, Antic Darko, Andjelic Bosko, Vukicevic Tomislav, Nikolic Vesna, Pejcic Ivica, Petkovic Ivan, Popovic Stevan, Popovic Lazar, Andjelkovic Nebojsa, Sretenovic Snežana, Lekovic Danijela, Smiljanic Mihajlo, Markovic Olivera, Knezevic Jelena, Vesna Kecman. Characteristics of 917 Non-Hodgkin's Lymphoma Patients in Serbia According to the Who Classification of Lymphoid Neoplasms - Lira National Register-Based Study (Meeting Abstract). Ann Oncol 2011 (22): 204.


    5. Mihaljevic Biljana, Andjelic Bosko, Antic Darko, Todorovic Milena, Vukicevic Tomislav, Nikolic Vesna, Pejcic Ivica, Petkovic Ivan, Popovic Snežana, Savic Igor, Popovic Lazar, Andjelkovic Nebojsa, Sretenovic Snežana, Knezevic Jelena, Kecman Vesna. Diffuse Large B-cell Lymphoma: Germinal Center Vs Non Germinal Center - Treatment Response on Immunochemotherapy. Serbian Lymphoma Study Group (Meeting Abstract). Ann Oncol 2011 (22) : 224-5.


    6. V Nikolić,D Antić, B Andjelić, M Todorović, T Vukićević, I Pejčić, I Petković, S Popović, L Popović, N Andjelković, S Sretenović, O Marković, J Knežević, B Mihaljević. Prognostički značaj Ki-67 indeksa u bolesnika sa difuznim krupnoćelijskim B-Limfomom koji su lečeni Ritzximabom plus CHOP-iskustva Srpske limfomske grupe. 2. Kongres hematologa Srbije/6th Balkan Day Haematology, Belgrade  2011. Abstract book pp 08, 23-5.


    7. Pejčić I, Vrbić S.Androgen receptors and predictors of response to hormonal therapy of prostate cancer. European School of Oncology, Niš 2002. Education Book, Prostate cancer, Pathology and hormonal aspects of diagnosis.


    8. Vrbić S, Pejčić I. Adjuvant chemotherapy of brest cancer patients under 35 years of age. European School of Oncology, Niš 2002. Education Book, Breast cancer, Adjuvant chemotherapy.


    9. Pejčić I. Poremećaji hemostaze u bolesnika sa diseminovanom malignom tumorskom bolešću. VI kongres hematologa i transfuziologa Jugoslavije (s medjunarodnim učešćem). Bilten za hematologiju i transfuziologiju 1990: 344.


    10. Petrović M, Pejćić I, Vrbić S, Mišković M, Dinić Ž. Feritin i timidin kinaza (TK) kod pacijenata sa malignim hemopatijama. VIII Kongres kancerologa Jugoslavije. Zbornik rezimea. Zagreb 1991.


    11. Radić S, Filipović S, Projević M, Pejčić I, Filipović B, Vrbić S. Značaj bioloških markera u praćenju toka i prognoze karcinoma prosatate. VIII Kongres kancerologa Jugoslavije. Zbornik rezimea. Zagreb 1991.


    12. Stanić A, Vrbić S, Pejčić I. Neuron specifična enolaza (NSE) i karcinoembrionalni antigen (CEA) u bolesnika sa malignim tumorima pluća. VIII Kongres kancerologa Jugoslavije. Zbornik rezimea. Zagreb 1991.


    13. Pejčić I, Vrbić S, Petrović M, Mišković M. Follow up of the serum feritin values in patients with non Hodgkin lymphomas. The Seventh Europian Conference of Clinical Oncology and Cancer Nursing . EU J Cancer 1993; 29a (6): 177.


    14. Filipović S, Filipović B, Veselinović S, Milutinopvić M, Stojanović D, Ilić R, Burić M, Pejčić I, Vrbić S, Potić-Zečavić N, Stojanović Z. Adjuvant chemotherapy in node negative breast cancer patients with cathepsin/D tumours. Journal of BUON 1996; 1 (1): 20.


    15. Vrbić S, Pejčić I, Petrović M. Adriamycin 90 mg/m2 and cisplatin 90 mg/m2 as primary chemotherapy in disseminated soft tissues sarcomas. Journal of B.U.ON. 1996; 1 (1): 27.


    16. Filipović S, Filipović R, Ilić R, Đorđević S, Vrbić S, Pejčić I, Veselinović S, Stojanović D. Breast Cancer Oestrogen-Receptor Negative Tumors, PS2 Expresion and DFI. 7th EORTC Breast Working Conference. Eu J Cancer 1996; 32A (2): 57.


    17. Filipović S, Filipović B, Kocić B, Petrović B, Veselinović S, Pejčić I, Vrbić S, Zečavić NP, Stojanović Z, Stojanović D. The raltionship of follow up tests with occurrence of overt metastatic desease. ECCO 9. Abstracts, Hamburg, 1997.


    18. Pejčić I, Vrbić S, Jovanović B, Filipović S. Altered coagulability in patients with metastatic melanoma. 2nd Balkan Congress of Oncology. Izmir Turkey, 1998.


    19. Bašić H, Nikolić D, Pejčić I, Višnjić M.Expressiion of HMB-45 and S-100 protein in malignant melanoma. Second Balkan congress of Oncology. J BUON 198.

  • Radovi na domaćim naučnim skupovima:

    1.Ivan Petković, Emilija Vagaja, Aleksandar Popović, Miljan Krstić, Ivica Pejčić. DA–EPOCH–R bez radioterapije vs. R–CHOP21+radioterapija su bez signifikante razlike na ishod lečenja bolesnika sa primarnim medijastinalnim B krupnoćelijskim limfomom. 4. Kongres hematologa Srbije, Niš 2019. Abstract book pp 008, 125.


    2. Ivan Petković, Emilija Vagaja, Aleksandar Popović, Miljan Krstić, Ivica Pejčić. Rezidualna PET/CT pozitivnost ne korelira sa rezistencijom/ progresijom bolesti nakon DA–EPOCH–R indukcije kod primarnog medijastinalnog B krupnoćelijskog limfoma. 4. Kongres hematologa Srbije, Niš 2019. Abstract book up 09, 100.                         


    3. Pejčić Ivica, Ivan Petković. Uticaj starosti pacijenata na izbor tretmana kod novodijagnostikovanih difuznih B krupnoćelijskih limfoma. 3. Kongres hematologa Srbije, Kragujevac 2015. Abstract book pp 39, 108-9. (M62)


    4. Ivan Petković, Ivica Pejčić, Svetislav Vrbić. Mirjana Balić.  Prediktivni značaj Muris skora kod bolesnika sa difuznim B krupnoćelijskim limfomom tretiranih imunohemioterapijom. 3. Kongres hematologa Srbije, Kragujevac 2015. Abstract book op 19, 120. (M64)


    5. Ivan Petković, Ivica Pejčić, Svetislav Vrbić, Mirjana Balić. Značaj nivoa beta 2 mikroglobulina kod bolesnika sa difuznim krupnoćelijskim B limfomom u eri primene rituksimaba. 3. Kongres hematologa Srbije, Kragujevac 2015. Abstract book p 53, 156. (M64)


    6. Ivan Petković, Ivica Pejčić, Svetislav Vrbić. Mirjana Balić.  Muški pol je faktor rizika za smrtni ishod kod bolesnika sa difuznim B krupnoćelijskim limfomom. 3. Kongres hematologa Srbije, Kragujevac 2015. Abstract book p 52, 156. (M64) 


    7. Miljan Krstić, Slavica Stojnev, Ivan Petković, Svetislav Vrbić, Ivica Pejčić. Ekspresija STAT3 u difuznom B-krupnoćelijskom limfomu nodalne i ekstranodalne lokalizacije. 3. Kongres hematologa Srbije, Kragujevac 2015. Abstract book p 55, 157. (M64)


    8. Vrbić S, Pejčić I, Simonović N, Petković I. Medikamentozna onkološka terapija medularnog tireoidnog karcinoma. Zbornik radova sa recenzijom. Medicinski fakultet Niš 2009: 86-90.


    9. Simonović N, Vrbić S, Pejčić I. Radioterapija medularnog karcinoma. Zbornik radova sa recenzijom. Medicinski fakultet Niš 2009: 91-5.


    10. Simonović S, Vrbić S, Pejčić I, Veličković M. Radioterapija karcinoma tireoideje. Dijagnostika i lečenje diferentovanog karcinoma štitaste žlezde, Zbornik radova sa recenzijom, Medicinski fakultet Niš 2008: 77-85.


    11. Pejčić I, Vrbić S, Šćekić M, Veličković M. Sistemska hemioterapija karcinoma štitaste žlezde. Dijagnostika i lečenje diferentovanog karcinoma štitaste žlezde, Zbornik radova sa recenzijom, Medicinski fakultet Niš 2008: 87-90.


    12. Vlajković M, Ilić S, Pejčić I, Vrbić S, Mihailović D. Karanikolić A, Matović M.
    Clinical usefulness of 99MTC-EDDA/HYNIC-TOC scintigraphy in diagnosing and staging of patients with medullary thyroid carcinoma. Thyroid and Parathyroid Surgery/(Proceedings Book)-Beograd: udruženje onkoloških hirurga Srbije 2008: 69.


    13. Pejčić I, Vrbić S. Regulacija angiogeneze kod karcinoma ovarijuma: uloga p53, VEGF i hipoksije. Savremeni pristupu dijagnostici i terapiji Karcinoma ovarijuma, Zbornik radova sa recenzijom, Medicinski fakultet Niš 2006: 103-8.


    14. Vrbić S, Pejčić I. Biološka i genska terapija epitelnih karcinoma jajnika. Savremeni pristupu dijagnostici i terapiji karcinoma ovarijuma, Zbornik radova sa recenzijom, Medicinski fakultet Niš 2006: 166-176.


    15. Pejčić I, Vrbić S, Šćekić M, Filipović S, Pejčić Lj, Filipović A. The effect of combined chemotherapy with or without potentiation with interferon alpha or tamoxifen for melanoma. 10th International Interuniversity Scientific Meeting Academy of Studenica. 2004


    16. Kostić G, Jovančić D, Marjanović Z, Pejčić I, Stojanović-Milojković L. Metastatski tumor nepoznatog primarnog ishodišta u školskog deteta. Pedijatrijski dani. Niš 2004: 327-8.


    17. Pejčić Lj, Pejčić I, Kostić G, Bjelaković B, Jovanović D. Procena kardiotoksičnosti antraciklinske citotoksične terapije. Pedijatrijski dani Srbije i Crne Gore. Niš 2003: 217


    18. Pejčić I, Vrbić S, Jovanović B, Filipović S, Veličković M. Altered parameters of coagulability in patients with metastatic tumours of unknown primary site. XXXVI Annual meeting of Oncology. Meeting abstracts. Belgrade, 1999.


    19. Vrbić S, Pejčić I, Jovanović B, Filipović S. Our experiences in chemotherapy of diseminated soft tissues sarcoma. XXXV Annual meeting of Oncology. Meeting abstracts. Belgrade, 1998.


    20. Vrbić S, Pejčić I, Jovanović B. Naša iskustva u lečenju relapsa i/ili rezistentnih non Hodgkin limfoma intermedijarnog i visokog rizika ESHAP protokolom. 8. Kongres hematologa Jugoslavije sa međunarodnim učćešćem. Zbornik sažetaka. Podgorica, 1998.


    21. Pejčić I, Vrbić S, Antović J, Filipović S, Bakić M. Pormećaji koagulacije u bolesnika sa metastatskim tumorima nepoznatog primarnog ishodišta. 8. Kongres hematologa Jugoslavije sa međunarodnim učćešćem. Zbornik sažetaka. Podgorica, 1998


    22. Pejčić I, Vrbić S, Filipović S, Petrović M. Vrednost serumskog feritina kao prognostičkog faktora u limfomima tipa non Hodgkin (NHL). Jugoslovenski hematolođki dani sa međunarodnim učešćem. Abstrakti radova. Niška Banja, 1996.


    23. Simonović N, Pejčić I, Ljubenković S, Krstić M, Veličković M, Bošnjaković P. Chondrosarcoma šake-prikaz slučaja. V godišnji stručni sastanak radiloga Srbije. Zbornik sažetaka. Zlatibor 1996


    24. Pejčić I, Vrbić S, Petrović M. Primena rekombinovanog G-CSF u pacijenata sa neutropenijom koja je indukovana citostatskom terapijom. Osnivački kongres hematologa Jugoslavije. Bilten za hematologiju 1994; 22 (1-2): 42.


    25. Vrbić S, Pejčić I, Petrović M. GM-CSF u terapiji pancitopenije izazvane zadesnim preoziranjem Lomustina–prikaz slučaja. Osnivački kongres hematologa Jugoslavije. Bilten za hematologiju 1994; 22 (1-2): 95.


    26. Pejčić I, Petrović M, Vrbić S, Mišković M. Koncentracija serumskog feritina u bolesnika sa limfomima tipa non Hodgkin. XXIX Kancerološka nedelja. Program i zbornik sažetaka. Beograd, 1992.


    27. Dinić Ž, Filipović S, Filipović D, Veljković D, Milutinović M, Radić S, Projević M, Pejčić I, Vrbić S. Rezultati primene polihemioterapije (VCR-5FU-CCNU) u bolesnika obolelih od kolorektalnog karcinoma. VII Kongres kancerologa Jugoslavije. Zbornik rezimea. Novi Sad, 1987.


    28. Dinić Ž, Filipović D, Filipović S, Radić S, Ćirković S,ProjevićM, Pejčić I, Vrbič S, Lilić Arsić S. Mogućnosti hemioterapijskog uticaja na primarne karcinome bronha i pluća.II Pneumoftiziološki dani. Zbornik radova “Malignom pluća”, Niš, 1987: 101-106.


    29. Đorđević D, Kostić M, Pejčić I, Vrbić S. Karcinom dojke i pluća. II Pneumoftiziološki dani. Zbornik radova “Malignom pluća”, Niš, 1987:59-65.


    30. Dinić Ž, Pejčić I, Vrbić S, Petrović M, Radić S, Filipović D, Filipović S, Dimitrijević D, Đorđević S, Projević M, Lazović M, Stevanović K, Raičević B. Hemioterapija malignih glioma, naša iskustva. XXII Kancerološka nedelja. Zbornik sažetaka. Beograd 1985.

Poslednji put izmenjeno utorak, 27 oktobar 2020 09:18